1. Torramade-Moix S, Palomo M, Vera M, Jerez D, Moreno-Castaño AB, Zafar MU, Rovira J, Diekmann F, Garcia-Pagan JC, Escolar G, Cases A, Diaz-Ricart M. Apixaban Downregulates Endothelial Inflammatory and Prothrombotic Phenotype in an In Vitro Model of Endothelial Dysfunction in Uremia. Cardiovasc Drugs Ther. 2020 Jul 10. doi: 10.1007/s10557-020-07010-z. 2. Ramírez-Bajo MJ, Martín-Ramírez J, Bruno S, Pasquino C, Banon-Maneus E, Rovira J, Moya-Rull D, Lazo M, Campistol JM, Camussi G, Diekmann F. Nephroprotective potential of mesenchymal stromal cells and their extracellular vesicles in a murine model of chronic cyclosporine nephrotoxicity. 3. Piñeiro GJ, Rovira J, Diekmann F, Esforzado N. Reply - Kidney graft outcomes in high immunological risk simultaneous liver-kidney transplants. Liver Transplantation. 2020 26(6):847-848. doi: 10.1002/lt.25761. 4. Piñeiro GJ, Rovira J, Montagud-Marrahí E, Torregrosa JV, Ríos J, Cucchiari D, Ugalde-Altamirano J, Ventura-Aguiar P, Gelpi R, Palou E, Colmenero J, Navasa M, Diekmann F, Esforzado N. Kidney graft outcomes in high immunological risk simultaneous liver-kidney transplants. Liver Transplantation. 2020 Apr;26(4):517-527. doi: 10.1002/lt.25726. 5. Ramirez-Bajo MJ, Rovira J, Lazo-Rodriguez M, Banon-Maneus E, Tubita V, Moya-Rull D, Hierro-Garcia N, Ventura-Aguiar P, Oppenheimer F, Campistol JM, Diekmann F. Impact of mesenchymal stromal cells and their extracellular vesicles in a rat model. Original Research, Frontiers in Cell Developmental Biology - Molecular Medicine. Front Cell Dev Biol. 2020 Jan 29;8:10. doi: 10.3389/fcell.2020.00010. 6. Cucchiari D, Rovira J, Diekmann F. Regulated cell death at the crossroad between ischemia-reperfusion injury and innate immunity in kidney transplantation. Transplantation 2020. 104(9):1772-1773. Commentary. 7. Cucchiari D, Ríos J, Molina-Andujar A, Montagud-Marrahi E, Revuelta I, Ventura-Aguiar P, Piñeiro GJ, De Sousa-Amorim E, Esforzado N, Cofán F, Torregrosa JV, Ugalde-Altamirano J, Ricart MJ, Rovira J, Torres F, Solè M, Campistol JM, Diekmann F, Oppenheimer F. Combination of calcineurin and mTOR inhibitors in kidney transplantation: a propensity score analysis based on current clinical practice. J Nephrol. 2020. 33(3):601-610. doi: 10.1007/s40620-019-00675-2. 8. Cucchiari D, Molina-Andujar A, Montagud-Marrahi E, Revuelta I, Rovira J, Ventura-Aguiar P, Piñeiro GJ, De Sousa-Amorim E, Esforzado N, Cofán F, Torregrosa JV1, Ricart MJ, Centellas-Pérez FJ, Solè M, Martorell J, Ríos J, Campistol JM, Diekmann F, Oppenheimer F. Use of de-novo mTOR inhibitors in hypersensitzed kidney trasplant recipients: experience from clinical practice. Transplantation. 2020 Aug;104(8):1686-1694. doi: 10.1097/TP.0000000000003021. 9. Tubita V, Segui-Barber J, Lozano JJ, Banon-Maneus E, Rovira J, Cucchiari D, Moya-Rull D, Oppenheimer F, Del Portillo H, Campistol1 JM, Diekmann F, Ramirez-Bajo MJ, Revuelta I. Effect of immunosuppression in miRNAs from extracellular vesicles of colorectal cancer and their influence on the pre-metastatic niche. Sci Rep. 2019 Aug 1;9(1):11177. doi: 10.1038/s41598-019-47581-y. 10. Rodriguez-Rodriguez AE, Donate-Correa J, Rovira J, Cuesto G, Luis-Ravelo D, Fernandes MX, Acevedo-Arozarena A, Diekmann F, Acebes A, Torres A, Porrini E. Inhibition of the mTOR pathway: a new mechanism of ß-cell toxicity induced by Tacrolimus. Am J Transplant. 2019 Dec;19(12):3240-3249. doi: 10.1111/ajt.15483. 11. Ventura-Aguiar P, Ferrer J, Rovira J, Diekmann F. Do we still need to demonstrate the survival benefit of pancreas transplantation? Am J Transplant. 2019 Apr;19(4):1241-1242. doi: 10.1111/ajt.15180. 12. Piñeiro GJ, De Sousa-Amorim E, Solé M, Ríos J, Lozano M, Cofán F, Ventura-Aguiar P, Cucchiari D, Revuelta I, Cid J, Palou E, Campistol JM, Oppenheimer F, Rovira J*, Diekmann F*. Rituximab, plasma exchange and immunoglobulins: an ineffective treatment for chronic active antibody-mediated rejection. BMC Nephrol. 2018 Oct 11;19(1):261. 13. Ventura-Aguiar P, Ferrer J, Revuelta I, Paredes D, de Sousa-Amorim E, Rovira J, Esmatjes E, Garcia-Valdecasas JC, Oppenheimer F, Diekmann F, Ricart MJ. Pancreas outcomes between living and deceased kidney donor recipients in pancreas after kidney transplantation. Nephrol Dial Transplant. 2018 Nov 1; 33(11):2052-2059. doi: 10.1093/ndt/gfy133. 14. Rovira J, Ramírez-Bajo MJ, Banon-Maneus E, Lazo-Rodríguez M, Moya-Rull D, Hierro-Garcia N, Tubita V, Piñeiro GJ, Revuelta I, Ventura-Aguiar P, Cucchiari D, Oppenheimer F, Brunet M, Campistol JM, Diekmann F. Tofacitinib halts progression of graft dysfunction in a rat model of mixed cellular and humoral rejection. Transplantation. 2018 Jul. 102(7):1075-1084. 15. Cucchiari D, Rovira J, Paredes D, Ventura-Aguiar P, Sanchez-Escuredo A, Solé M, Adalia R, Oppenheimer F, Diekmann F, Revuelta I. Association of Brain-Dead Donors' Terminal Inflammation With Delayed Graft Function in Kidney Transplant Recipients. Transplant Proc. 2017 Dec;49(10):2260-2264. doi: 10.1016/j.transproceed.2017.10.003. 16. Rovira J, Diekmann F, Campistol JM, Ramírez-Bajo MJ. Uso terapéutico de las vesículas extracelulares en insuficiencia renal aguda y crónica. Nefrologia. 2017 Mar - Apr;37(2):126-137. doi: 10.1016/j.nefro.2016.04.006. 17. Martina MN, Ramirez Bajo MJ, Bañon-Maneus E, Moya Rull D, Hierro-Garcia N, Revuelta I, Campistol JM, Rovira J*, Diekmann F*. Inhibition of JAK3 and PKC via Immunosuppressive Drugs Tofacitinib and Sotrastaurin Inhibits Proliferation of Human B Lymphocytes In Vitro. Transplant Proc. 2016 Nov;48(9):3046-3052. doi:10.1016/j.transproceed.2016.07.052. 18. Hernández-Sierra A*, Rovira J*, Petit A, Moya-Rull D, Mazuecos MA, Sánchez-Fructuoso AI, Errasti P, Idoate MÁ, Cruzado JM, Vidal A, Diekmann F, Oppenheimer F, Campistol JM, Revuelta I. Role of HHV-8 and mTOR pathway in post-transplant Kaposi sarcoma staging. Transpl Int. 2016 Sep;29(9):1008-16. doi: 10.1111/tri.12800. 19. Rovira J, Renner P, Sabet-Baktach M, Eggenhofer E, Koehl GE, Lantow M, Lang SA, Schlitt HJ, Campistol JM, Geissler EK, Kroemer A. Cyclosporine A Inhibits the T-bet Dependent anti-Tumor Response of CD8+ T cells. Am J Transplant. 2016 Apr; 16(4):1139-47. doi: 10.1111/ajt.13597. 20. Rovira J, Ramírez-Bajo MJ, Banon-Maneus E, Moya-Rull D, Ventura-Aguiar P, Hierro-Garcia N, Lazo-Rodriguez M, Revuelta I, Torres A, Oppenheimer F, Campistol JM, Diekmann F. mTOR inhibition: reduced insulin secretion and sensitivity in a rat model of metabolic syndrome. Transplantation Direct: 2016 Jan 22;2(2):e65. doi: 10.1097/TXD.0000000000000576. eCollection 2016 Feb. 21. Eggenhofer E, Sabet-Rashedi M, Lantow M, Renner P, Rovira J, Koehl GE, Schlitt HJ, Geissler EK, Kroemer A. RORγt(+) IL-22-producing NKp46(+) cells protect from hepatic ischemia reperfusion injury in mice. J Hepatol. 2016 Jan; 64(1):128-34. doi: 10.1016/j.jhep.2015.08.023. 22. Canha C, Ferreira R, Rovira J, Moya-Rull D, Castells A, Diekmann F, Oppenheimer F, Campistol JM, Revuelta I. A Case of Esophageal Adenocarcinoma on long-term Rapamycin Monotherapy. Transpl Int. 2015 Oct; 28(10):1240-4. doi:10.1111/tri.12600. 23. Lantow M, Eggenhofer E, Sabet-Baktach M, Renner P, Rovira J, Koehl GE, Schlitt HJ, Geissler EK, Kroemer A. CD27low Natural Killer Cells Prolong Allograft Survival in Mice by Controlling Alloreactive CD8+ T Cells in a T-Bet-Dependent Manner. Transplantation. 2015 Feb; 99(2):391-9. 24. Renner P, Rovira J, Klein C, Schlitt HJ, Geissler EK, Kroemer A. KLRG1(+) natural killer cells protect against pulmonary metastatic disease by immunosurveillance. Oncoimmunology. 2014 Apr 8;3:e28328. doi: 10.4161/onci.28328 25. Banon-Maneus E, Rovira J, Ramirez-Bajo MJ, Moya-Rull D, Hierro-Garcia N, Takenaka S, Diekmann F, Eickelberg O, Königshoff M, Campistol JM. Wnt pathway activation in long term remnant rat model. Biomed Res Int. 2014; 2014:324713. doi: 10.1155/2014/324713. 26. Malaisé M*, Rovira J*, Renner P, Eggenhofer E, Sabet-Baktach M, Lantow M, Lang SA, Koehl GE, Farkas SA, Loss M, Agha A, Campistol JM, Schlitt HJ, Geissler EK, Kroemer A. KLRG1+ NK Cells Protect T-bet-Deficient Mice from Pulmonary Metastatic Colorectal Carcinoma. J Immunol. 2014 Feb 15;192(4):1954-61. doi: 10.4049/jimmunol.1300876. 27. Sabet-Baktach M, Eggenhofer E, Rovira J, Renner P, Lantow M, Farkas SA, Malaisé M, Edtinger K, Shaotang Z, Koehl GE, Dahlke MH, Schlitt HJ, Geissler EK, Kroemer A. Double-Deficiency for RORγt and T-bet Drives Th2-Mediated Allograft Rejection in Mice. J Immunol. 2013 Oct 15; 191(8):4440-4446. doi:10.4049/jimmunol.1301741. 28. Diekmann F, Campistol JM, Rovira J, Budde K, Neumayer H-H, Oppenheimer F, Flechner SM. Treatment with Sirolimus is associated with less weight gain after kidney transplantation. Transplantation. 2013; 96(5):480-6. doi: 10.1097/TP.0b013e31829a9231. 29. Eggenhofer E, Rovira J, Sabet-Baktach M, Groell A, Scherer MN, Dahlke MH, Farkas SA, Loss M, Koehl GE, Lang SA, Melter M, Schlitt HJ, Geissler EK, Kroemer A. Unconventional RORγt+ T Cells Drive Hepatic Ischemia Reperfusion Injury. J Immunol. 2013; 191(1):480-487. doi: 10.4049/jimmunol.1202975. 30. Rovira J, Sabet-Baktach M, Eggenhofer E, Lantow M, Koehl GE, Schlitt HJ, Campistol JM, Geissler EK, Kroemer A. A color-coded reporter model to study the effect of immunosuppressants on CD8+ T-cell memory in antitumor and alloimmune response. Transplantation. 2013; 95(1):54-62. doi:10.1097/TP.0b013e318276d358. 31. Irimia JM, Rovira J, Nielsen JN, Guerrero M, Wojtaszewski JF, Cussó R. Hexokinase 2, glycogen synthase and phosphorylase play a key role in muscle glycogen supercompensation. PLoS One. 2012; 7(7):e42453. doi: 10.1371/journal.pone.0042453. 32. Rovira J, Diekmann F, Ramírez-Bajo MJ, Bañón-Maneus E, Moya-Rull D, Campistol JM. Sirolimus-Associated Testicular Toxicity: Detrimental But Reversible. Transplantation. 2012; 93(9):874-879. doi: 10.1097/TP.0b013e31824bf1f0. 33. Revuelta I, Moya-Rull D, García-Herrera A, Rovira J, Ayala de la Peña F, Misiego A, Guzmán F, Oppenheimer F, Albanell J, Campistol JM. Role of Oncogenic Pathways and KRAS/BRAF Mutations in the Behavior of Colon Adenocarcinoma in Renal Transplant Patients. Transplantation. 2012; 93(5):509-517. doi: 10.1097/TP.0b013e318242be46. 34. Rovira J, Irimia JM, Guerrero M, Cadefau JA, Cussó R. Upregulation of heart PFK-2/FBPase-2 isozyme in skeletal muscle after persistent contraction. Pflugers Archiv-European Journal of Physiology. 2012; 463(4):603-613. doi: 10.1007/s00424-011-1068-5. 35. Diekmann F, Rovira J, Diaz-Ricart M, Arellano EM, Vodenik B, Jou JM, Vives-Corrons JL, Escolar G, Campistol JM. mTOR inhibition and erythropoiesis: microcytosis or anemia? Nephrol Dial Transplant. 2012; 27(2):537-541. doi: 10.1093/ndt/gfr318. 36. Vodenik B, Rovira J, Diekmann F, Revuelta I, Oppenheimer F, Campistol JM. Preemptive use of Mammalian target of rapamycin inhibitors in living donor transplantation. Transplant Proc. 2011; 43(7):2568-2573. doi: 10.1016/j.transproceed.2011.08.001. 37. Bañón-Maneus E, Diekmann F, Carrascal M, Quintana LF, Moya-Rull D, Bescós M, Ramírez-Bajo MJ, Rovira J, Gutierrez-Dalmau A, Solé-González A, Abián J, Campistol JM. “Two-Dimensional Difference Gel Electrophoresis Urinary Proteomic Profile in the Search of Nonimmune Chronic Allograft Dysfunction Biomarkers.” Transplantation. 2010; 89(5):548-58. doi: 10.1097/TP.0b013e3181c690e3. 38. Rovira J, Arellano EM, Carreras J, Campos B, Vodenik B, Bañon-Maneus E, Ramírez-Bajo MJ, Moya-Rull D, Solé-González A, Hernández A, Revuelta I, Quintana LQ, Howat WJ, Campistol JM, Diekmann F. Mammalian Target of Rapamycin Inhibition Prevents Glomerular Hypertrophy in a Model of Renal Mass Reduction. Transplantation 2009; 88(5): 646–652. doi: 10.1097/TP.0b013e3181b24463. 39. Vodenik B, Rovira J, Campistol JM. Mammalian target of rapamycin and diabetes: what does the current evidence tell us? Transplant Proc. 2009; 41(6 Suppl):S31-S38. doi: 10.1016/j.transproceed.2009.06.159. 40. Rovira J, Marcelo Arellano E, Burke JT, Brault Y, Moya-Rull D, Bañón-Maneus E, Ramírez-Bajo MJ, Gutiérrez-Dalmau A, Revuelta I, Quintana LF, Campistol JM, Diekmann F. Effect of mTOR inhibitor on body weight: from an experimental rat model to human transplant patients. Transpl Int. 2008; 21(10):992-998. doi: 10.1111/j.1432-2277.2008.00710.x. 41. Arellano EM, Campistol JM, Oppenheimer F, Rovira J, Diekmann F. Sirolimus monotherapy as maintenance immunosuppression: single-center experience in 50 kidney transplant patients. Transplant Proc. 2007; 39(7):2131-2134. doi: 10.1016/j.transproceed.2007.06.056. 42. Diekmann F, Rovira J, Carreras J, Arellano EM, Bañón-Maneus E, Ramírez-Bajo MJ, Gutiérrez-Dalmau A, Brunet M, Campistol JM. Mammalian target of rapamycin inhibition halts the progression of proteinuria in a rat model of reduced renal mass. J Am Soc Nephrol. 2007; 18(10):2653-2660. doi: 10.1681/ASN.2007010087. 43. Bernal CA, Rovira J, Colandré ME, Cussó R, Cadefau JA. Effects of dietary cis and trans unsaturated and saturated fatty acids on the glucose metabolites and enzymes of rats. Br J Nutr. 2006; 95(5):947-954. doi: 10.1079/bjn20061756.